The further subgroup analysis (Figure 3B–3P) revealed that high FHL2 expression was associated with poor OS of patients with lung adenocarcinoma (P = 0.0110), lung squamous cell carcinoma (P = 0.0160), stage II (P = 0.0059), T2 (P < 0.0001), N2 (P = 0.0033) and M0 (P = 0.0048). The gene discussed is FHL2; the disease is lung adenocarcinoma.